- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: July 2016
- Public Summary Document (PSD) July 2016 PBAC Meeting - PDF
- Public Summary Document (PSD) July 2016 PBAC Meeting - Word
Daclizumab – July 2016
Daclizumab: 150 mg/mL solution for injection, 1 mL pen-filled pen 150 mg/mL solution for injection, 1 mL syringe, Zinbryta®
Last updated
11 November 2016